Skip to main content
SpringerLink
Log in

CancerTYPE ID test cost effective in cancer diagnosis

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • bioTheranostics. bioTheranostics CancerTYPE ID(Rm) Molecular Test Is a Cost-Effective Approach to Standardizing Diagnosis & Improving Metastatic Cancer Care, Study Shows. Media Release : 14 Jul 2014. Available from: URL: http://www.biotheranostics.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CancerTYPE ID test cost effective in cancer diagnosis. PharmacoEcon Outcomes News 708, 4 (2014). https://doi.org/10.1007/s40274-014-1416-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1416-8

Search

Navigation